Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fatty acid study aims to unlock secrets of rare metabolic disease

NCT ID NCT06623032

Knowledge-focused Sponsor: University of Copenhagen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study looks at how medium-chain and long-chain fatty acids affect metabolism in people with Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) and healthy individuals. Researchers will measure ketone bodies, resting metabolic rate, and other factors after participants consume these fats. The goal is to better understand the body's response in MCADD, which could lead to improved dietary advice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Medium-Chain Fatty Acid (MCFA) and Long-Chain Fatty Acid (LCFA)
What this could lead to
If successful, this study could provide insights into how different fats affect people with MCADD, potentially guiding dietary recommendations to manage the condition better.
What could go wrong
This is a small, early-stage study with only 30 participants, so results may not apply broadly. It focuses on short-term metabolic effects, not long-term outcomes or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria MCADD patients: * Male or female * Age between 18-80 years old * Diagnosed Medium-chain acyl-CoA dehydrogenase deficiency (MCADD Inclusion Criteria Healthy Participants: * Male or female * Age between 18-80 years old Exclusion Criteria both MCADD patients and healthy participants: * Diabetes * Kidney- or liver disease * Use of beta blockers or diuretics * Pregnant, lactating or planning to become pregnant within the study period * Regular intake of substantial amounts of coconut oil, palm kernel oil or any other source abundant in MCFA * Ongoing cancer treatment * Metabolic or absorptive disorders, gastric bypass operation, or use of medication affecting metabolism or food absorption * Inability, physically or mentally, to comply with the procedure required by the study protocol as evaluated by the primary investigator, study manager or clinical responsible

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medium-chain acyl-coa dehydrogenase deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

medium chain acyl-CoA dehydrogenase deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medium-chain acyl-coa dehydrogenase deficiency

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Copenhagen

    RECRUITING

    Copenhagen, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.